Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema
Public ClinicalTrials.gov record NCT05333055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The DRAGONS study is a non-interventional, prospective study that will 1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various stages of diabetic retinopathy (DR) and diabetic macular edema (DME) as well as other retinal pathologies, and 2. correlate a broad array of aqueous humor disease state biomarkers with DR severity, DME anti-vascular endothelial growth factor (VEGF) responsiveness, and other retinal pathologies.
Study identification
- NCT ID
- NCT05333055
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 107 participants
Conditions and interventions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 9, 2022
- Primary completion
- May 14, 2024
- Completion
- May 14, 2024
- Last update posted
- Jan 23, 2025
2022 – 2024
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina Consultants of Texas | Bellaire | Texas | 77401 | — |
| Retina Consultants of Texas | Katy | Texas | 77494 | — |
| Retina Consultants of Texas | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Diabetic Retinopathy trials
Other public records listing Diabetic Retinopathy. Sorted by last update posted; newest first. Not a recommendation.
- NCT07592273: Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema Recruiting
- NCT05079399: Biomarker of Diabetic Retinopathy Recruiting
- NCT07588100: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy Recruiting
- NCT06257082: Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities Recruiting
- NCT06321302: A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy Active, not recruiting
- NCT06943599: Strategies for Improving Linkage-to-Care After Eye Disease Screening Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05333055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 23, 2025 · Synced Sep 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05333055 live on ClinicalTrials.gov.